Arrhythmia Research Technology Announces New Chairman and Organization Changes.Business Editors & Medical/Biotech Writers AUSTIN, Texas--(BUSINESS WIRE)--July 31, 2000 Effective July 1, 2000, E.P. Marinos, a current director and former President of Arrhythmia arrhythmia (ārĭth`mēə), disturbance in the rate or rhythm of the heartbeat. Various arrhythmias can be symptoms of serious heart disorders; however, they are usually of no medical significance except in the presence of Research Technology (AMEX AMEX See: American Stock Exchange :HRT HRT abbr. hormone replacement therapy Hormone replacement therapy (HRT) Also called estrogen replacement therapy, this controversial treatment is used to relieve the discomforts of menopause. ) ("ART"), will become Chairman of the Board of Directors for ART and its subsidiary, Micron Products Inc. Anthony A. Cetrone, 72, the former chairman retired July 1, 2000. Richard A. Campbell has recently joined the Company as Vice President of Finance and Chief Financial Officer. His responsibilities include both the ART and Micron entities. James Rouse has been named General Manager and Vice President of Operations for Micron. Rouse plus several key managers will also fulfill the duties of the Office of the Presidency in an effort to streamline management and still maintain a highly competitive operation. ART sells equipment used in the cardiovascular field for diagnosing and treating patients with irregular heartbeat and irregular electrical conduction patterns of the heart. Proprietary product lines include the 1200 EPX EPX Enterprise Private Exchange (tm), LP-Pac Q, PREDICTOR series, the Tri-Pac and silver-silver chloride plated sensors. The ART Web site is located at http://www.arthrt.com. Forward-looking statements made herein are based on current expectations of the Company and involve a number of risks and uncertainties and should not be considered as guarantees of future performance. These statements are made under the Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The factors that could cause actual results to differ materially include: interruptions or cancellation of existing contracts, impact of competitive products and pricing, product demand and market acceptance, risks, the presence of competitors with greater financial resources than the Company, product development and commercialization risks and an inability to arrange additional debt or equity financing. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion